Salarius Pharmaceuticals Inc (OQ:SLRX)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Jun 12, 2024 08:00 am ET

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will...

Mar 22, 2024 04:05 pm ET

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results...

Feb 22, 2024 08:00 am ET

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, today announced that its Board of Directors is implementing a series of...

Jan 16, 2024 08:00 am ET

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,773,080, titled “Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating...

Jan 03, 2024 08:30 am ET

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as active and recruiting on...

Nov 07, 2023 08:30 am ET

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to receive guidance regarding the development program for seclidemstat to treat...

Aug 10, 2023 04:05 pm ET

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 08, 2023 04:05 pm ET

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

Jul 11, 2023 08:30 am ET

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jun 12, 2023 08:00 am ET

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

May 16, 2023 04:05 pm ET

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023 08:00 am ET

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 11, 2023 08:00 am ET

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 09, 2023 08:00 am ET

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 01, 2023 08:30 am ET

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Apr 20, 2023 08:30 am ET

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 04, 2023 04:02 pm ET

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Mar 27, 2023 08:30 am ET

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 15, 2023 11:00 am ET

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 07, 2023 08:00 am ET

Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces...

Feb 16, 2023 08:30 am ET

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Jan 27, 2023 08:30 am ET

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 20, 2023 07:53 am ET

Thinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ?

NEW YORK, Jan. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLRX, APPH, ALLY, JAGX, and IONQ.

Jan 19, 2023 08:30 am ET

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 05, 2023 08:00 am ET

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

Dec 13, 2022 08:01 am ET

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022 08:00 am ET

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 08, 2022 08:00 am ET

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

Dec 01, 2022 08:00 am ET

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Nov 10, 2022 08:30 am ET

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 03, 2022 09:57 am ET

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Oct 27, 2022 08:30 am ET

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 19, 2022 08:30 am ET

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 18, 2022 08:30 am ET

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Oct 14, 2022 08:43 am ET

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that it will effect a 1-for-25 reverse stock split at...

Sep 20, 2022 12:00 pm ET

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Sep 13, 2022 08:00 am ET

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today issued the following letter to stockholders from its President...

Aug 22, 2022 08:30 am ET

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of the Mayo Clinic to its open-label Phase 1/2 trial...

Aug 08, 2022 08:30 am ET

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022,...

Aug 04, 2022 08:30 am ET

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarc

Aug 02, 2022 08:30 am ET

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics...

Jul 29, 2022 09:15 am ET

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will report its second quarter 2022 financial...

Jun 09, 2022 07:33 am ET

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will participate in the 2022 BIO International...

May 18, 2022 04:10 pm ET

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David...

May 12, 2022 04:05 pm ET

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the first...

May 12, 2022 08:30 am ET

Thinking about buying stock in Stealth BioTherapeutics, Allena Pharmaceuticals, Salarius Pharmaceuticals, Coupang, or Lordstown Motors?

NEW YORK, May 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, ALNA, SLRX, CPNG, and RIDE.

May 11, 2022 04:05 pm ET

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, hematologic cancers and other cancers, today announced the successful...

May 05, 2022 07:30 am ET

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast...

Apr 22, 2022 08:30 am ET

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements with several...

Mar 10, 2022 04:05 pm ET

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the full...

Mar 03, 2022 07:31 am ET

Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast...

Feb 17, 2022 08:01 am ET

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius...

Feb 08, 2022 08:00 am ET

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius...

Feb 03, 2022 07:30 am ET

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has...

Jan 13, 2022 07:00 am ET

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced a definitive agreement with DeuteRx, LLC...

Jan 06, 2022 12:45 pm ET

Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"

Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company will present at H.C. Wainwright...

Dec 29, 2021 08:03 am ET

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, today announced an important dosing milestone in the Phase 1/2 Sarcoma...

Dec 20, 2021 07:35 am ET

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Dec 15, 2021 08:31 am ET

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Dec 14, 2021 07:35 am ET

Virtual Conference for Life Sciences Companies Broadcast Live December 16th

Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com

Nov 29, 2021 08:01 am ET

Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, announced today that its chief...

Nov 04, 2021 04:05 pm ET

Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, today reported important corporate...

Oct 26, 2021 08:01 am ET

Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced that the Company...

Oct 07, 2021 09:05 am ET

Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therape

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital announced today...

Oct 05, 2021 08:01 am ET

Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Sep 30, 2021 04:35 pm ET

Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sep 28, 2021 07:01 am ET

Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a...

Sep 27, 2021 08:03 am ET

Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Sep 22, 2021 07:33 am ET

Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership

Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research...

Sep 20, 2021 08:35 am ET

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations and...

Sep 20, 2021 07:33 am ET

Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced its inclusion in the...

Sep 15, 2021 08:03 am ET

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Sep 10, 2021 08:35 am ET

Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th

Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...

Sep 08, 2021 08:13 am ET

Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Aug 25, 2021 08:30 am ET

Thinking about buying stock in Salarius Pharmaceuticals, Oscar Health, Aeva Technologies, Powerbridge Technologies, or Academy Sports & Outdoors?

NEW YORK, Aug. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLRX, OSCR, AEVA, PBTS, and ASO.

Aug 19, 2021 08:30 am ET

Thinking about buying stock in Coherus Biosciences, Macy's, Salarius Pharmaceuticals, Verb Technology, or Senseonics?

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHRS, M, SLRX, VERB, and SENS.

Aug 12, 2021 02:00 pm ET

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur,...

Aug 12, 2021 09:00 am ET

Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference

Investors can register at https://www.diamondequityresearch.com/conferences/ or using the company specific links below. Agenda – August 17th, 2021 9:00-9:30VolitionRX Limited (NYSE:VNRX)9:40-10:10Blue Star Foods Corp. (OTC:BSFC)10:20-10:50Color...

Aug 05, 2021 07:32 am ET

Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, today reported important corporate...

Jul 29, 2021 07:33 am ET

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

Jul 14, 2021 08:05 am ET

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit

Jul 13, 2021 07:33 am ET

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Jul 09, 2021 07:33 am ET

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive...

Jun 17, 2021 08:03 am ET

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Jun 15, 2021 07:30 am ET

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the initiation of a clinical trial to...

Jun 10, 2021 01:30 pm ET

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Jun 07, 2021 07:35 am ET

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 19, 2021 05:01 pm ET

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 12, 2021 04:05 pm ET

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its...

May 05, 2021 07:05 am ET

Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results

Apr 29, 2021 07:30 am ET

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted...

Apr 19, 2021 07:30 am ET

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts...

Mar 18, 2021 04:05 pm ET

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its...

Mar 11, 2021 04:15 pm ET

Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results

Mar 08, 2021 04:05 pm ET

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

Mar 04, 2021 08:30 am ET

Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the pricing of an underwritten public...

Mar 03, 2021 04:05 pm ET

Salarius Announces Proposed Public Offering of Common Stock

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has commenced an underwritten...

Feb 24, 2021 07:30 am ET

Thinking about buying stock in Sundial Growers, electroCore, Arlo Technologies, Salarius Pharmaceuticals, or CNS Pharmaceuticals?

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ECOR, ARLO, SLRX, and CNSP.

Feb 24, 2021 07:00 am ET

Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Feb 22, 2021 07:30 am ET

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Salarius CEO David Arthur will...

Feb 17, 2021 07:34 am ET

Thinking about buying stock in Comstock Mining, Oncolytics Biotech, Salarius Pharmaceuticals, Altimmune, or Creative Realities?

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LODE, ONCY, SLRX, ALT, and CREX.

Feb 17, 2021 07:30 am ET

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Feb 16, 2021 08:31 am ET

Thinking about buying stock in Salarius Pharmaceuticals, KemPharm, Ocular Therapeutix, Boxlight Corp, or Endra Life Sciences?

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLRX, KMPH, OCUL, BOXL, and NDRA.

Feb 16, 2021 07:30 am ET

Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference

Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it will participate in the BIO CEO & Investor...

Feb 10, 2021 07:31 am ET

Thinking about buying stock in Sundial Growers, Neptune Wellness Solutions, Gamida Cell, FSD Pharma, or Salarius Pharmaceuticals?

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, NEPT, GMDA, HUGE, and SLRX.

Jan 21, 2021 08:05 am ET

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from...

Jan 15, 2021 07:30 am ET

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D.,...

Jan 13, 2021 07:30 am ET

Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.9 million payment...

Dec 22, 2020 07:30 am ET

Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"

Dec 11, 2020 11:32 am ET

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has entered into agreements...

Dec 10, 2020 09:28 am ET

Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.8 million payment...

Nov 17, 2020 07:30 am ET

Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David...

Nov 11, 2020 04:05 pm ET

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with pediatric cancers, solid tumors and other cancers, today reported its corporate and financial...

Nov 04, 2020 07:30 am ET

Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing treatments for pediatric cancers, solid tumors and other cancers, announced that the Company will host a conference call and live audio webcast on...

Oct 13, 2020 07:30 am ET

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conference...

Sep 21, 2020 08:35 am ET

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...

Sep 14, 2020 08:35 am ET

Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020

Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...

Sep 10, 2020 07:30 am ET

Salarius Pharmaceuticals to Present at Upcoming Investor Conferences

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming investor conferences during the month of September....

Aug 31, 2020 05:00 pm ET

LD Micro - 360 Companies Set to Present - this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Aug 27, 2020 10:00 am ET

Salarius Pharmaceuticals to Present During Virtual LD 500 Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present during the 2020 LD 500...

Aug 12, 2020 04:05 pm ET

Salarius Pharmaceuticals Reports Business Highlights and Second Quarter 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today reported its corporate and financial results for the second quarter ended June 30, 2020....

Aug 05, 2020 09:30 am ET

Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the Company will host a conference call and live audio webcast on Wednesday, August 12,...

Aug 05, 2020 09:00 am ET

LD Micro Announces Preliminary List of Presenters for the LD-500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Aug 05, 2020 07:30 am ET

Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead...

Aug 03, 2020 04:05 pm ET

Salarius Announces Closing of $6.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Salarius Pharmaceuticals, Inc.. (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the...

Jul 30, 2020 09:23 am ET

Salarius Announces Pricing of $5.3 Million Underwritten Public Offering

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a...

Jul 29, 2020 04:15 pm ET

Salarius Announces Proposed Public Offering of Common Stock

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock. All of...

Jul 29, 2020 04:05 pm ET

Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers caused by dysregulated gene expression, today announced the expansion of its ongoing clinical trial of seclidemstat in patients with relapsed or...

Jul 28, 2020 08:00 am ET

Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has relocated its corporate operations within the Texas Medical Center in Houston. In...

Jul 23, 2020 08:00 am ET

Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that Nadeem Q. Mirza, M.D., M.P.H., has joined Salarius as Senior Vice President...

Jun 02, 2020 09:00 am ET

Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administration’s Oncologic Drugs Advisory Committee

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that the U.S. Food and Drug Administration (FDA) has invited the company to present...

May 27, 2020 08:00 am ET

Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that a Trial in Progress poster of the ongoing Phase 1/2 clinical trial of seclidemstat...

May 14, 2020 04:05 pm ET

Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results

May 14, 2020 08:00 am ET

Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract on the Phase 1/2 clinical trial of seclidemstat in Ewing sarcoma has...

May 07, 2020 04:05 pm ET

Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that the Company will host a conference call and live audio webcast on Thursday, May 14,...

Apr 29, 2020 07:30 am ET

Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that its Board of Directors has unveiled nominations and updates to the Board in advance...

Apr 22, 2020 08:00 am ET

Salarius Pharmaceuticals to Deliver Virtual Presentation at the Emerging Growth Invitational

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur, will deliver a virtual presentation at the...

Mar 23, 2020 04:18 pm ET

Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

Mar 04, 2020 08:00 am ET

Salarius Announces Allowance of New European Patent Covering Seclidemstat

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the U.S. and global intellectual property (IP) portfolio...

Mar 02, 2020 08:00 am ET

Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

Feb 11, 2020 04:05 pm ET

Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its previously announced underwritten public offering, with total gross...

Feb 10, 2020 08:00 am ET

Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital...

Feb 07, 2020 08:31 am ET

Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to...

Feb 05, 2020 08:00 am ET

Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 04, 2020 08:00 am ET

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, today announced the publication of a scientific paper entitled, “The Novel Reversible LSD1 Inhibitor...

Dec 19, 2019 08:00 am ET

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, announced today that its chief executive officer, David Arthur, will...

Dec 17, 2019 08:00 am ET

Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern...

Dec 16, 2019 08:00 am ET

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its lead investigational drug candidate, Seclidemstat, has been granted Fast Track...

Dec 12, 2019 08:00 am ET

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the acceptance of an abstract at the “Epigenetics Symposium: 15 Years of Lysine Demethylases: From...

Nov 13, 2019 08:00 am ET

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial results for the quarter ended September 30, 2019. Third Quarter 2019...

Oct 28, 2019 08:00 am ET

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has entered into a $10.9 million common stock purchase agreement, including a $1.0 million initial...

Oct 14, 2019 08:00 am ET

Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences. Management will provide an overview of Salarius’...

Oct 08, 2019 08:00 am ET

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital...

Sep 24, 2019 08:00 am ET

Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the Safety Review Committees overseeing the Phase 1/2 clinical study of Seclidemstat in Ewing sarcoma...

Sep 13, 2019 08:00 am ET

Salarius Pharmaceuticals Announces Senior Leadership Changes

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to the new role of Chief Business Officer and the appointment of Mark...

Sep 12, 2019 08:00 am ET

Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer Awareness Month, designated as the month of September. Recognizing the work...

Aug 26, 2019 07:00 am ET

Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma....

Aug 12, 2019 08:00 am ET

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur, issued an open letter to Salarius’ stockholders following...

Jul 29, 2019 09:02 am ET

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President and Chief Executive Officer David Arthur and other members of the management team, will ring...

Jul 24, 2019 04:05 pm ET

Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed the sale of HOTSHOT, a novel consumer beverage formerly marketed by Flex Innovation Group LLC,...

Jul 22, 2019 08:05 am ET

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has enrolled the first patient in a Phase 1 clinical study of the company’s lead compound, Seclidemstat,...

Jul 22, 2019 08:00 am ET

Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.’s wholly owned subsidiary...

Ad blocking detected

Salarius Pharmaceuticals Inc (OQ:SLRX)

Business Focus: Biotechnology & Medical Research